Leia Inc. Partners With Anatomage to Enable 3D Stereoscopic Learning Through Anatomage VR
Leia Inc., the leading 3D experience platform leveraging proprietary Nanotechnology and AI to democratize the Metaverse, partnered with Anatomage Inc, a market leader in medical imaging technology, to enable a cost-effective 3D medical education solution leveraging Leia’s Lume Pad tablet and the Anatomage’s software.
Released by Anatomage, Anatomage VR allows users to project 3D stereoscopic images of Anatomage’s digital bodies and pathology library on Leia’s Lume Pads. The award-winning Lume Pads 3D Lightfield display enables naturally immersive, easy-to-use, eyewear-free 3D learning. Combined with the Anatomage VR application, users can interact with two realistic digital bodies created from real human data that are highly segmented and annotated. The interactive interface of the tablet allows for swiping, panning and zooming through gross anatomy bodies and an extensive patient library through the Anatomage VR.
“Leia’s 3D Lightfield displays make it interactive and easy to bridge virtual and in-person by offering naturally immersive learning,” said David Fattal, CEO of Leia Inc. “Leia is the first company whose software and nanotechnology screen underlay makes the Metaverse and 3D experiences instantly accessible to anyone on any device at scale — and we’re excited to work with Anatomage to make medical education more accessible.”
“Our customers wanted to see our content jump off the screen and we’re delighted to deliver this offering,” said Jack Choi, CEO of Anatomage. “With Anatomage VR, our customers can bring the excitement of 3D to their students, engaging them with a more immersive and interactive learning platform — rich quality content to provide an enjoyable learning experience.”
Designed to accompany accredited high school anatomy and life science programs, Anatomage VR on the Lume Pad provides a portable, personalized learning solution to allow students to review anatomy concepts autonomously in class, at home, and from anywhere.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more